Compound Overview
PT-141 (bremelanotide) stands apart in the research peptide landscape. Where most studied compounds act on metabolic, repair, or growth hormone pathways, PT-141 is a melanocortin receptor agonist — a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts through the central nervous system.
PT-141 binds primarily to melanocortin receptors MC3R and MC4R, which are concentrated in the hypothalamus. Research has focused on how activation of these receptors influences downstream signaling pathways. Unlike compounds that act on vascular smooth muscle, PT-141's activity is centrally mediated — which is precisely what makes it a valuable research tool for studying melanocortin system dynamics.
Bremelanotide has an FDA-approved pharmaceutical counterpart (Vyleesi), which distinguishes it from many research-only compounds — there is a substantial body of published clinical literature characterizing its pharmacology. For researchers, this makes PT-141 a well-documented reference compound for melanocortin pathway studies, receptor binding assays, and central signaling research.
PT-141 follows standard lyophilized peptide handling: bacteriostatic water reconstitution, refrigerated storage, and protection from light. As with all compounds in this category, it is sold strictly for research use only.
Plato Peptides carries PT-141 in 10mg and 20mg research formats, each with third-party COA documentation available.